F-11,461

In this article, we will approach F-11,461 from different perspectives, with the aim of providing a comprehensive view on this topic/person/date. We will analyze its impact on today's society, its evolution over time and the possible implications it has in various areas. In addition, we will examine its relevance in the current context, as well as the different opinions and theories that exist in this regard. Through this comprehensive analysis, we aim to provide the reader with a more complete understanding of F-11,461 and encourage reflection on its importance in our daily lives.

F-11,461
Identifiers
  • 2--1-piperazinyl]butyl]-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC23H29N5O3
Molar mass423.517 g·mol−1
3D model (JSmol)
  • O=C1C=NN(C(=O)N1C)CCCCN2CCN(C3=CC=CC4=CC=C(O)C=C43)CC2
  • InChI=InChI=1S/C23H29N5O3/c1-25-22(29)17-24-28(23(25)30)11-4-3-10-26-12-14-27(15-13-26)21-7-5-6-18-8-9-19(31-2)16-20(18)21/h5-9,16-17H,3-4,10-15H2,1-2H3/i2-1
  • Key:GKTQBPYMIGXPKG-JVVVGQRLSA-N

F-11,461 is a naphthylpiperazine drug that acts as an agonist of the 5-HT1A receptor (Ki = 1.36 nM) that has been used as a radioligand in PET studies. It possesses modest affinity for the 5-HT7 (Ki = 9.1 nM) and D4 (Ki = 8.5 nM) receptors, although the interaction of F-11,461 with these receptors is not detectable with PET due to their relative scarcity in the brain.[1]

See also

References

  1. ^ Kumar JS, Majo VJ, Hsiung SC, Millak MS, Liu KP, Tamir H, et al. (January 2006). "Synthesis and in vivo validation of 2-{4-butyl}-4-methyl-2H-triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand". Journal of Medicinal Chemistry. 49 (1): 125–134. doi:10.1021/jm050725j. PMID 16392798.